Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Morgan Stanley sees a risk to Pfizer's EPS guidance

Published 01/06/2023, 10:08 AM
Updated 01/06/2023, 10:11 AM
© Reuters Morgan Stanley sees a risk to Pfizer's (PFE) EPS guidance
PFE
-

By Sam Boughedda

In a note to clients Friday, Morgan Stanley analysts said the firm sees downside risk to Pfizer's (NYSE:PFE) EPS guidance.

The analysts explained that Pfizer will provide 1st time 2023 guidance in conjunction with fourth-quarter earnings on January 31 and the company previously noted that they plan to provide COVID franchise-level guidance (similar to 2022 practice).

In addition, Morgan Stanley raises its Paxlovid 2023 estimate for the new U.S. contract.

"At PFE's recent R&D day the company guided to 7-9% revenue growth for 2023, excluding COVID revenues and F/X. By our prior math this implies 2023 revenue for the base (ex-COVID) of ~$47.9bn-$48.8bn using the mid point of 2022 guidance of $44.75bn (excluding COVID revenues)," writes Flynn. "We model 2023 revenues (ex-COVID) of $45.1bn (4% YoY growth), but this includes an F/X headwind so it is not a clean comp to PFE's guide. PFE also noted that this year the average gross price increase across the portfolio was 3.7% vs. 2.7% last year, which was influenced by the current inflationary environment."

"We are raising our 2023 Paxlovid (oral COVID drug) estimate to $9.7bn from $7.7bn following the recently announced U.S. contract," the analysts added. "As a result our total 2023 revenue estimate goes to $71.1bn from $69.1bn (vs. consensus of $77.9bn) and our 2023 EPS goes to $4.16 from $3.90 (vs. consensus of $4.87)."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.